| No DMARDs, N = 79 | bDMARD, N = 52 | Methotrexate, N = 34 | p value a/b/c |
---|---|---|---|---|
Demographic characteristics | ||||
 Sex (M/F) | 31/48 | 29/23 | 17/17 | −/−/− |
 Age, (mean ± SD) | 49.3 ± 12.0 | 48.0 ± 11.7 | 50.9 ± 11.3 | −/−/− |
 Body mass index, (mean ± SD) | 28.6 ± 6.2 | 29.0 ± 6.0 | 28.8 ± 6.4 | −/−/− |
 Smokers, N (%) | 24 (30) | 12 (23) | 7 (21) | −/−/− |
 Menopause, N (%) | 21 (27) | 12 (23) | 7 (21) | −/−/− |
 Previous fracture, N (%)‡ | 4 (5) | 2 (4) | 2 (6) | −/−/− |
Disease-specific characteristics | ||||
 Duration of PSO (years), (mean ± SD) | 18.1 ± 16.1 | 20.2 ± 11.1 | 20.3 ± 16.4 | −/−/− |
 Duration of PsA (years), (mean ± SD) | 2.9 ± 5.2 | 7.8 ± 7.4 | 4.6 ± 7.4 | < 0.001/0.011/0.018 |
 MDA, N (%) | 28 (35) | 25 (48) | 22 (65) | −/0.004/− |
 DAPSA | ||||
  DAPSA score, (mean ± SD) | 17.0 ± 11.4 | 12.3 ± 9.6 | 15.8 ± 17.8 | 0.009/−/− |
  Remission, N (%) | 7 (9) | 10 (19) | 6 (18) | −/−/− |
  Low activity, N (%) | 29 (37) | 25 (48) | 13 (38) | −/−/− |
  Moderate activity, N (%) | 24 (30) | 12 (23) | 9 (27) | −/−/− |
  High activity, N (%) | 12 (15) | 2 (4) | 4 (12) | 0.040/−/− |
 Nail involvement, N (%) | 20 (25) | 7 (14) | 8 (24) | −/−/− |
 Scalp involvement, N (%) | 35 (44) | 8 (15) | 8 (24) | 0.002/−/− |
 PASI (units), (mean ± SD) | 4.0 ± 4.7 | 1.2 ± 2.7 | 2.1 ± 7.9 | < 0.001/0.001/− |
 DLQI (units), (mean ± SD) | 7.5 ± 6.5 | 3.2 ± 5.3 | 6.0 ± 5.3 | 0.043/−/− |
 HAQ (units), (mean ± SD) | 0.6 ± 0.5 | 0.5 ± 0.5 | 0.7 ± 0.8 | −/−/− |
 Diabetes mellitus, N (%) | 2 (3) | 3 (6) | 2 (6) | −/−/− |
 Hypertension, N (%) | 19 (24) | 14 (27) | 5 (15) | −/−/− |
Autoantibody status | ||||
 Positive low-titer ACPA, N (%)* | 1 (1) | 0 | 1 (3) | −/−/− |
 Positive low-titer RF, N (%)** | 3 (4) | 0 | 1 (3) | −/−/− |
Anti-rheumatic and bone treatments | ||||
 Vitamin D supplementation, N (%) | 10 (13) | 11 (21) | 9 (27) | −/−/− |
 Bisphosphonates, N (%) | 0 | 1 (2) | 0 | −/−/− |
 Current glucocorticoids, N (%) | 0 | 6 (12) | 5 (15) | 0.002/0.001/− |
 Former glucocorticoids intake, N (%) | 4 (5) | 13 (25) | 5 (15) | 0.001/−/− |
 Duration of glucocorticoids intake (years), (mean ± SD) | 1.1 ± 1.0 | 2.8 ± 2.2 | 0.4 ± 0.2 | −/−/0.034 |